Daily Piece: Positive Outcomes from Trial Using GLP-1 Agonist and SGLT-2 Inhibitor

In practice, I often find it helpful to use glucagon-like )GLP-1) receptor agonist in combination with sodium glucose cotransporter-2 (SGLT-2) inhibitor for type 2 diabetes as they tackle type 2 diabetes from different avenues. Using these two drug classes together creates synergy. Findings from a recent study of semaglutide, GLP-1 agonist, being added to SGLT-2 inhibitor (either alone or in combination with metformin or sulfonylurea) in persons with Type 2 diabetes who have inadequately controlled glucose improved glycemic control. Greater A1c and weight reduction were positive outcomes. Please click below to read this trial summary.


This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#synergy #GLP1 #agonist #SGLT2 #inhibitor

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Leave a Reply

Your email address will not be published. Required fields are marked *